, and the 36-month beta value for AKTX is at 1.29. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The average price suggested by analysts for AKTX is $4.00, which is $2.58 above the current market price. The public float for AKTX is 84.82M, and currently, shorts hold a 0.27% of that float. The average trading volume for AKTX on May 26, 2023 was 491.44K shares.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
AKTX) stock’s latest price update
The stock of Akari Therapeutics Plc (NASDAQ: AKTX) has decreased by -8.74 when compared to last closing price of 0.19.Despite this, the company has seen a loss of -15.54% in its stock price over the last five trading days.
AKTX’s Market Performance
Akari Therapeutics Plc (AKTX) has seen a -15.54% fall in stock performance for the week, with a -8.74% decline in the past month and a -52.56% plunge in the past quarter. The volatility ratio for the week is 15.74%, and the volatility levels for the past 30 days are at 12.01% for AKTX. The simple moving average for the past 20 days is -7.36% for AKTX’s stock, with a -66.40% simple moving average for the past 200 days.
AKTX Trading at -13.58% from the 50-Day Moving Average
After a stumble in the market that brought AKTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.23% of loss for the given period.
Volatility was left at 12.01%, however, over the last 30 days, the volatility rate increased by 15.74%, as shares sank -3.72% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -32.79% lower at present.
During the last 5 trading sessions, AKTX fell by -15.54%, which changed the moving average for the period of 200-days by -88.81% in comparison to the 20-day moving average, which settled at $0.1868. In addition, Akari Therapeutics Plc saw -63.10% in overturn over a single year, with a tendency to cut further losses.
In conclusion, Akari Therapeutics Plc (AKTX) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.